Biogen (NASDAQ:BIIB) Price Target Raised to $177.00 at Piper Sandler

Biogen (NASDAQ:BIIB) had its target price boosted by Piper Sandler from $157.00 to $177.00 in a research report sent to investors on Monday morning, Marketbeat reports. The firm currently has a neutral rating on the biotechnology company’s stock.

A number of other analysts have also weighed in on the stock. Truist Financial upped their target price on shares of Biogen from $142.00 to $190.00 and gave the stock a “hold” rating in a report on Thursday, January 8th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Biogen in a report on Tuesday, January 13th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Biogen in a research report on Monday. Weiss Ratings restated a “hold (c-)” rating on shares of Biogen in a research report on Monday, December 29th. Finally, Wall Street Zen lowered Biogen from a “buy” rating to a “hold” rating in a research note on Sunday, November 9th. Thirteen research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $206.21.

Biogen Stock Performance

NASDAQ:BIIB opened at $193.81 on Monday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. Biogen has a 52-week low of $110.04 and a 52-week high of $202.41. The firm has a market cap of $28.43 billion, a price-to-earnings ratio of 22.00, a PEG ratio of 1.70 and a beta of 0.16. The business’s fifty day moving average is $177.26 and its 200 day moving average is $157.48.

Biogen (NASDAQ:BIIB) last posted its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same quarter in the previous year, the firm earned $3.44 EPS. The company’s quarterly revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Research analysts predict that Biogen will post 15.83 EPS for the current year.

Insider Transactions at Biogen

In other Biogen news, insider Priya Singhal sold 748 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $179.30, for a total transaction of $134,116.40. Following the transaction, the insider directly owned 6,271 shares in the company, valued at $1,124,390.30. This trade represents a 10.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.18% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Biogen

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in Biogen by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 17,447,092 shares of the biotechnology company’s stock worth $3,070,514,000 after purchasing an additional 157,857 shares during the period. State Street Corp boosted its position in Biogen by 1.0% during the second quarter. State Street Corp now owns 7,468,807 shares of the biotechnology company’s stock valued at $938,007,000 after buying an additional 71,897 shares during the period. Geode Capital Management LLC boosted its position in Biogen by 3.2% during the fourth quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock valued at $736,435,000 after buying an additional 130,618 shares during the period. Invesco Ltd. grew its stake in shares of Biogen by 4.2% during the third quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock valued at $338,731,000 after buying an additional 98,001 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Biogen in the second quarter worth about $284,358,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and upbeat guidance: Biogen reported fourth‑quarter and FY results ahead of expectations, prompting analysts to raise forecasts and price targets — a direct earnings-driven positive catalyst. Biogen Posts Q4 Beat, Analysts Raise Price Targets
• Positive Sentiment: Regulatory progress for Leqembi: A biologics license application for a subcutaneous formulation of Leqembi was designated for priority review — this could expand prescribing convenience and bolster long‑term franchise value. Biologics License Application for Subcutaneous LEQEMBI Designated for Priority Review
• Positive Sentiment: Geographic expansion: Reports that China fast‑tracked at‑home use of Leqembi add another potential growth market for the Alzheimer’s franchise. Biogen stock to pop again? China fast-tracks Leqembi
• Positive Sentiment: Big analyst upgrades: RBC raised its price target to $233 (Outperform) and HC Wainwright raised its target to $228 (Buy), both signalling double‑digit upside from current levels and reflecting confidence in Leqembi and cash‑flow prospects. RBC Raises Price Target on Biogen to $233
• Neutral Sentiment: Mixed/neutral analyst stances: Several shops (Citigroup, Piper Sandler, Wedbush, Truist) nudged price targets higher but kept Neutral/Hold ratings, leaving investor guidance mixed. Analyst Price Target Moves (Citigroup, Piper, Wedbush, Truist)
• Negative Sentiment: Franchise pressure and execution risk: Analysis points to MS‑franchise weakness and near‑term growth limits, which keep some analysts cautious despite the Alzheimer’s upside. Biogen FY25 Earnings: Stable EPS Amid MS Franchise Pressure

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.